MICRO-HOPE

18 Aug, 10

0

MICRO-HOPE

Study Patients

3577 high-risk diabetics (aged > 55 yrs; had previous CV event i.e. CAD, stroke or PVD; or diabetes plus one other CV risk factor i.e. hypertension, microalbuminuria, total cholesterol >5.2 mmol/L, HDL-C <0.9 mmol/L or current smoking)

Study Groups

Ramipril 10 mg/day vs placebo

Median Study Period

4.5 years

Results

Significantly reduces risk of primary composite outcome of MI, stroke or CV death by 25% vs placebo
Significantly reduces the combined outcome of overt nephropathy, dialysis or laser therapy by 16% vs placebo
Significantly reduces individual outcomes vs placebo

Conclusion

Significant reduction in CV events was observed with ramipril in high-risk patients with diabetes
These benefits with ramipril were independent of the BP reduction observed with the drug

Lancet 2000;355:253-9

0